|
AR073380A1
(es)
|
2008-09-25 |
2010-11-03 |
Takeda Pharmaceutical |
Composicion farmaceutica solida. comprimido multicapa
|
|
EP2351743A4
(en)
|
2008-10-27 |
2012-05-09 |
Takeda Pharmaceutical |
BICYCLIC COMPOUND
|
|
EP2371826A4
(en)
|
2008-12-29 |
2012-06-27 |
Takeda Pharmaceutical |
NEW CONNECTION WITH CONDENSED RINGS AND ITS USE
|
|
JP5657578B2
(ja)
|
2009-06-09 |
2015-01-21 |
武田薬品工業株式会社 |
新規な縮合環化合物およびその用途
|
|
EP2460523B1
(en)
|
2009-07-28 |
2017-01-04 |
Takeda Pharmaceutical Company Limited |
Tablet
|
|
HRP20151425T1
(hr)
|
2009-08-10 |
2016-01-29 |
Samumed, Llc |
Inhibitori indazola wnt signalnog puta i njihove terapeutske uporabe
|
|
US20110112158A1
(en)
*
|
2009-11-11 |
2011-05-12 |
David Robert Bolin |
Benzisoxazole analogs as glycogen synthase activators
|
|
JP5822844B2
(ja)
|
2009-12-21 |
2015-11-24 |
サミュメッド リミテッド ライアビリティ カンパニー |
1H−ピラゾロ[3,4−b]ピリジンおよびその治療的使用
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
ES2546130T3
(es)
|
2010-04-27 |
2015-09-18 |
Takeda Pharmaceutical Company Limited |
Derivados de compuestos bicíclicos y su uso como inhibidores de ACC
|
|
BR112012032055B8
(pt)
|
2010-06-16 |
2019-11-12 |
Takeda Pharmaceuticals Co |
cristal de cloridrato de 1-(4-metoxibutil)-n-(2-metilpropil)-n-[(3s,5r)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1h-benzimidazol-2-carboxamida, medicamento, e, uso do cristal
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
EP2617726A4
(en)
|
2010-09-17 |
2014-05-14 |
Takeda Pharmaceutical |
DIABETES THERAPEUTIC
|
|
AR084032A1
(es)
|
2010-11-30 |
2013-04-17 |
Takeda Pharmaceutical |
Compuesto biciclico
|
|
MX2013009526A
(es)
|
2011-02-17 |
2013-10-01 |
Takeda Pharmaceutical |
Metodo de produccion de derivado de dihidrobenzofurano opticamente activo.
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
RS58462B1
(sr)
|
2011-09-14 |
2019-04-30 |
Samumed Llc |
Indazol-3-karboksamidi i njihova upotreba kao inhibitora signalnog puta wnt/b-katenina
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
CN103998432A
(zh)
|
2011-10-24 |
2014-08-20 |
武田药品工业株式会社 |
双环化合物
|
|
JP6129850B2
(ja)
|
2012-01-12 |
2017-05-17 |
武田薬品工業株式会社 |
Mch受容体拮抗剤としてのベンゾイミダゾール誘導体
|
|
EP2816032A4
(en)
|
2012-02-13 |
2015-09-30 |
Takeda Pharmaceutical |
AROMATIC RING CONNECTION
|
|
JP6095580B2
(ja)
|
2012-02-13 |
2017-03-15 |
武田薬品工業株式会社 |
芳香環化合物
|
|
US20150011549A1
(en)
|
2012-02-15 |
2015-01-08 |
Takeda Pharmaceutical Company Limited |
Tablet
|
|
WO2013125732A1
(en)
|
2012-02-24 |
2013-08-29 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound
|
|
JPWO2013147026A1
(ja)
|
2012-03-29 |
2015-12-14 |
武田薬品工業株式会社 |
芳香環化合物
|
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
|
SG11201407148XA
(en)
|
2012-05-04 |
2014-11-27 |
Samumed Llc |
1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
|
US9505772B2
(en)
|
2012-05-10 |
2016-11-29 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound
|
|
JPWO2013168759A1
(ja)
|
2012-05-10 |
2016-01-07 |
武田薬品工業株式会社 |
芳香環化合物
|
|
KR102145641B1
(ko)
|
2012-06-05 |
2020-08-18 |
다케다 야쿠힌 고교 가부시키가이샤 |
고형 제제
|
|
JP2015127299A
(ja)
|
2012-07-19 |
2015-07-09 |
武田薬品工業株式会社 |
固形製剤
|
|
JP6355648B2
(ja)
|
2013-01-08 |
2018-07-11 |
サミュメッド リミテッド ライアビリティ カンパニー |
Wntシグナル伝達経路の3−(ベンゾイミダゾール−2−イル)−インダゾール阻害剤およびそれらの治療的使用
|
|
US9605000B2
(en)
|
2013-03-14 |
2017-03-28 |
Takeda Pharmaceutical Company Limited |
Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
|
|
US10005720B2
(en)
|
2013-04-05 |
2018-06-26 |
North Carolina Central University |
Compounds useful for the treatment of metabolic disorders and synthesis of the same
|
|
WO2015005489A1
(en)
|
2013-07-09 |
2015-01-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
ES2672992T3
(es)
|
2013-08-09 |
2018-06-19 |
Takeda Pharmaceutical Company Limited |
Compuesto aromático
|
|
JO3442B1
(ar)
|
2013-10-07 |
2019-10-20 |
Takeda Pharmaceuticals Co |
مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
|
|
US9346776B2
(en)
|
2014-02-13 |
2016-05-24 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic compound
|
|
US9428470B2
(en)
|
2014-02-13 |
2016-08-30 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
CN104151216B
(zh)
*
|
2014-08-22 |
2016-08-17 |
山东铂源药业有限公司 |
一种拉帕替尼侧链的合成方法
|
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040182A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
|
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
|
WO2016040188A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016115272A1
(en)
|
2015-01-13 |
2016-07-21 |
Vanderbilt University |
Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
|
US10231956B2
(en)
|
2015-08-03 |
2019-03-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
WO2017023972A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023989A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023986A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
|
|
US10329309B2
(en)
|
2015-08-03 |
2019-06-25 |
Samumed, Llc |
3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
US10226448B2
(en)
|
2015-08-03 |
2019-03-12 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
|
|
WO2017024026A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
|
US10350199B2
(en)
|
2015-08-03 |
2019-07-16 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
|
US10285983B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
|
|
WO2017024025A1
(en)
|
2015-08-03 |
2017-02-09 |
Sunil Kumar Kc |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
US10206909B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
US10188634B2
(en)
|
2015-08-03 |
2019-01-29 |
Samumed, Llc |
3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
WO2017023993A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023980A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
|
US10383861B2
(en)
|
2015-08-03 |
2019-08-20 |
Sammumed, LLC |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
|
US10463651B2
(en)
|
2015-08-03 |
2019-11-05 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
|
|
US10206908B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
|
EP3896066A3
(de)
|
2015-08-07 |
2021-12-08 |
Bayer CropScience Aktiengesellschaft |
2-(het)aryl-substituierte kondensierte heterocyclen-derivate als schädlingsbekämpfungsmittel
|
|
AU2016348639B2
(en)
|
2015-11-06 |
2022-09-08 |
Samumed, Llc |
Treatment of osteoarthritis
|
|
GB201604970D0
(en)
|
2016-03-23 |
2016-05-04 |
Syngenta Participations Ag |
Improvements in or relating to organic compounds
|
|
AR108325A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
SG10201912248RA
(en)
|
2016-06-01 |
2020-02-27 |
Samumed Llc |
Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
|
|
JP2019535672A
(ja)
|
2016-10-21 |
2019-12-12 |
サミュメッド リミテッド ライアビリティ カンパニー |
インダゾール−3−カルボキサミドの使用方法およびwnt/β−カテニンシグナル伝達経路阻害剤としてのそれらの使用
|
|
KR102558716B1
(ko)
|
2016-11-07 |
2023-07-21 |
사뮤메드, 엘엘씨 |
단일-투여량, 즉시-사용가능한 주사용 제제
|
|
JOP20180029A1
(ar)
|
2017-03-30 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركب حلقي غير متجانس
|
|
JOP20180028A1
(ar)
|
2017-03-31 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركب ببتيد
|
|
WO2018181847A1
(ja)
|
2017-03-31 |
2018-10-04 |
武田薬品工業株式会社 |
芳香環化合物
|
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
|
CN110117278B
(zh)
*
|
2018-02-07 |
2022-07-19 |
石家庄以岭药业股份有限公司 |
烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
|
|
MY205468A
(en)
|
2018-03-23 |
2024-10-22 |
Carmot Therapeutics Inc |
Modulators of g-protein coupled receptors
|
|
US20210403420A1
(en)
|
2018-08-27 |
2021-12-30 |
Scohia Pharma, Inc. |
Benzoate compound
|
|
EP3856768A2
(en)
|
2018-09-24 |
2021-08-04 |
Takeda Pharmaceutical Company Limited |
Gip receptor agonist peptide compounds and uses thereof
|
|
JP7511548B2
(ja)
|
2018-09-24 |
2024-07-05 |
武田薬品工業株式会社 |
Gip受容体アゴニストペプチド化合物及びその使用
|
|
CR20220371A
(es)
|
2020-02-07 |
2022-10-27 |
Gasherbrum Bio Inc |
Agonistas heterocíclicos de glp-1
|
|
WO2021193984A2
(en)
|
2020-03-25 |
2021-09-30 |
Takeda Pharmaceutical Company Limited |
Qd dosing of gip receptor agonist peptide compounds and uses thereof
|
|
AR121649A1
(es)
|
2020-03-25 |
2022-06-22 |
Takeda Pharmaceuticals Co |
Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos
|
|
CN112062754B
(zh)
*
|
2020-09-24 |
2022-06-21 |
深圳市华先医药科技有限公司 |
一种合成Dorzagliatin的中间体的制备方法
|
|
CN114369097B
(zh)
*
|
2020-10-15 |
2023-07-14 |
山东轩竹医药科技有限公司 |
杂芳环类AhR抑制剂
|
|
CN112300028B
(zh)
*
|
2020-10-27 |
2022-03-11 |
无锡双启科技有限公司 |
一种2-氨基-3-甲氧基-5-溴苯腈的制备方法
|
|
US12152018B2
(en)
|
2021-01-08 |
2024-11-26 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with STING activity
|
|
AU2022272251A1
(en)
|
2021-05-13 |
2023-11-16 |
Carmot Therapeutics Inc. |
Modulators of g-protein coupled receptors
|
|
JP2025509180A
(ja)
|
2022-03-04 |
2025-04-11 |
上海瓔黎薬業有限公司 |
五員ヘテロアリール環構造含有化合物、その医薬組成物及び使用
|
|
CN119137124A
(zh)
|
2022-03-09 |
2024-12-13 |
加舒布鲁姆生物公司 |
杂环glp-1激动剂
|
|
EP4496797A1
(en)
|
2022-03-21 |
2025-01-29 |
Gasherbrum Bio, Inc. |
5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
|
|
WO2023198140A1
(en)
|
2022-04-14 |
2023-10-19 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
WO2024112831A1
(en)
*
|
2022-11-22 |
2024-05-30 |
Maze Therapeutics, Inc. |
Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof
|
|
WO2024125602A1
(en)
|
2022-12-15 |
2024-06-20 |
Gasherbrum Bio, Inc. |
Salts and solid forms of a compound having glp-1 agonist activity
|
|
WO2024131869A1
(en)
|
2022-12-22 |
2024-06-27 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
WO2024138048A1
(en)
|
2022-12-22 |
2024-06-27 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
WO2024169952A1
(en)
|
2023-02-16 |
2024-08-22 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
TW202506102A
(zh)
|
2023-06-30 |
2025-02-16 |
美商迦舒布魯姆生物有限公司 |
雜環的glp-1促效劑
|
|
TW202519220A
(zh)
|
2023-07-13 |
2025-05-16 |
美商雅空嘉閣生物公司 |
化合物、組合物及方法
|
|
WO2025015268A1
(en)
|
2023-07-13 |
2025-01-16 |
Aconcagua Bio, Inc. |
Modulators of calcitonin receptor and/or amylin receptor activity
|
|
WO2025045208A1
(en)
|
2023-08-31 |
2025-03-06 |
Gasherbrum Bio, Inc. |
Heteroaryl-heterocycloalkyl-based glp-1 agonists
|
|
WO2025137307A1
(en)
|
2023-12-20 |
2025-06-26 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
WO2025154020A1
(en)
|
2024-01-19 |
2025-07-24 |
Takeda Pharmaceutical Company Limited |
Improved gip receptor agonist peptide compounds and uses thereof
|
|
WO2025154021A1
(en)
|
2024-01-19 |
2025-07-24 |
Takeda Pharmaceutical Company Limited |
Improved gip receptor agonist peptide compounds and uses thereof
|
|
WO2025171340A1
(en)
|
2024-02-08 |
2025-08-14 |
Aconcagua Bio, Inc. |
The treatment of calcitonin- and/or amylin-receptor associated conditions
|
|
WO2025171341A2
(en)
|
2024-02-08 |
2025-08-14 |
Aconcagua Bio, Inc. |
Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
|